Alexion Pharmaceuticals

Contact Us Legal Sitemap

References

  1. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995 Nov 9;333(19):1253-8.
  2. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. J A M A 2005 Apr 6;293(13):1653-62.
  3. Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005 Dec 1;106(12):3699-709.
  4. Hill A, Rother RP, Wang X, Sapsford RJ, Collinson PO, Gaze DC, et al. Eculizumab Reduces Pulmonary Hypertension through Inhibition of Hemolysis-Associated Nitric Oxide Consumption in Patients with Paroxysmal Nocturnal Hemoglobinuria. ASH Annual Meeting Abstracts 2008 Nov 16;112(11):486.
  5. Hill A, X Wang, RJ Sapsford, RP Rother, AL Farrell, PG Dip, et al. Nitric Oxide Consumption and Pulmonary Hypertension in Patients with Paroxysmal Nocturnal Hemoglobinuria. American Society of Hematology . 2005. Ref Type: Abstract
  6. Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci U S A 1996 Aug 6;93(16):8563-8.
  7. Peng T, Hao L, Madri JA, Su X, Elias JA, Stahl GL, et al. Role of C5 in the development of airway inflammation, airway hyperresponsiveness, and ongoing airway response. J Clin Invest 2005 Jun 1;115(6):1590-600.
  8. Wang H, Rollins SA, Gao Z, Garcia B, Zhang Z, Xing J, et al. Complement inhibition with an anti-C5 monoclonal antibody prevents hyperacute rejection in a xenograft heart transplantation model. Transplantation 1999 Dec 15;68(11):1643-51.
  9. Wang H, Jiang J, Liu W, Kubelik D, Chen G, Gies D, et al. Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine. Transplantation 2005 May 15;79(9):1121-7.
  10. Halstead SK, Humphreys PD, Goodfellow JA, Wagner ER, Smith RA, Willison HJ. Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Ann Neurol 2005 Aug;58(2):203-10.
  11. Halstead SK, Zitman FM, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008 May;131(Pt 5):1197-208.
  12. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000 May;105(10):1363-71.
  13. Wang Y, Rollins SA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci U S A 1995 Sep 12;92(19):8955-9.
  14. Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006 Sep 21;355(12):1233-43.
  15. Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004 Feb 5;350(6):552-9.
  16. Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008 Feb 15;111(4):1840-7.
  17. Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007 Dec 1;110(12):4123-8.
  18. Socie G, Hillmen P, Muus P, Schubert J, Duhrsen U, Risitano AM, et al. Sustained Improvements in Transfusion Requirements, Fatigue and Thrombosis with Eculizumab Treatment in Paroxysmal Nocturnal Hemoglobinuria. ASH Annual Meeting Abstracts 2007 Nov 16;110(11):3672.
  19. Alexion Pharmaceuticals Inc. Soliris (eculizumab) full prescribing information. United States Food and Drug Administration; 2007 Mar 16.
  20. Weitz IC, Ghods M, Rochanda L, Prazavi P, Zwicker J, Furie B, et al. Eculizumab Therapy Results in Rapid and Sustained Decreases in Markers of Thrombin Generation and Inflammation in Patients with PNH. ASH Annual Meeting Abstracts 2008 Nov 16;112(11):407.
  21. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med 2006 Jun 8;354(23):2473-83.
  22. Hillmen P, Modupe O.Elebute, Richard Kelly, Alvaro Urbano-Ispizua, Russell P.Rother, Chieh-Lin Fu, et al. High Incidence of Progression to Chronic Renal Insufficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood 110[11]. 11-16-2007. Ref Type: Abstract
  23. Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, et al. Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria: AEGIS Phase II Clinical Study Results. ASH Annual Meeting Abstracts 2008 Nov 16;112(11):3438.
  24. Dunn DE, Tanawattanacharoen P, Boccuni P, Nagakura S, Green SW, Kirby MR, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 1999 Sep 21;131(6):401-8.
  25. Socie G, Mary JY, de Gramont A., Rio B, Leporrier M, Rose C, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 1996 Aug 31;348(9027):573-7.
  26. Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood 2002 Dec 1;100(12):3897-902.
  27. Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M, et al. Minor population of CD55-. Blood 2006 Feb 15;107(4):1308-14.
  28. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007 Nov;25(11):1256-64.
  29. Roth A, A Huettmann, U Duehrsen, T Philipp. Long-Term Efficacy of the Terminal Complement Inhibitor Eculizumab in a Patient with Cold Agglutinin Disease. Blood 112. 2008. Ref Type: Abstract
  30. de LB, Mertens K, de Groot PG. Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism. Nat Clin Pract Rheumatol 2008 Apr;4(4):192-9.
  31. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002 Mar 7;346(10):752-63.
  32. Erkan D, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome: where do we stand? Arthritis Rheum 2003 Dec;48(12):3320-7.
  33. Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005 Jul;52(7):2120-4.
  34. Stahl AL, Vaziri-Sani F, Heinen S, Kristoffersson AC, Gydell KH, Raafat R, et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 2008 Jun 1;111(11):5307-15.
  35. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006 Aug 15;108(4):1267-79.
  36. Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008 Nov;23(11):1957-72.
  37. Chatelet V, V Fremeaux-Bacchi, M Ficheux, T Lobbedez, B Huralult-Deligny. Efficacy of Eculizumab in a Plasmatherapy-dependent Patient with AHUS with C3 Mutation Following Plasmatherapy Withdrawal. Blood 112. 2008. Ref Type: Abstract
  38. Nuernberger J, O Witzke, RP Rother, T Philipp, U Vester, H Baba, et al. Successful Treatment of AHUS with Complement Inhibitor Eculzumab. Blood 112. 2008. Ref Type: Abstract
  39. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest 2006 Nov;116(11):2843-54.
  40. hou Y, B Gong, C Richmonds, F Lin, RP Rother, HJ Kaminski, et al. Anti-C5 Antibody Treatment Ameliorates Weakness in Experimentally Acquired Myasthenia Gravis. J Immunol 2007;179:8562-7.
  41. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004 May 19;291(19):2367-75.
  42. Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, Wokke JH, Van den Berg LH. Multifocal motor neuropathy. Lancet Neurol 2005 May;4(5):309-19.
  43. Putzu GA, Figarella-Branger D, Bouvier-Labit C, Liprandi A, Bianco N, Pellissier JF. Immunohistochemical localization of cytokines, C5b-9 and ICAM-1 in peripheral nerve of Guillain-Barre syndrome. J Neurol Sci 2000 Mar 1;174(1):16-21.
  44. Halstead SK, Zitman FM, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008 May;131(Pt 5):1197-208.
  45. http://www.cancer.gov/cancerinfo/pdg/treatment/CLL/patient. 2009. Ref Type: Internet Communication
  46. http://seer.cancer.gov/statfacts/html/clyl.html. 2009. Ref Type: Internet Communication
  47. Kretz-Rommel A, Qin F, Dakappagari N, Ravey EP, McWhirter J, Oltean D, et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol 2007 May 1;178(9):5595-605.
  48. Kawasaki BT, Farrar WL. Cancer stem cells, CD200 and immunoevasion. Trends Immunol 2008 Oct;29(10):464-8.
  49. McWhirter JR, Kretz-Rommel A, Saven A, Maruyama T, Potter KN, Mockridge CI, et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci U S A 2006 Jan 24;103(4):1041-6.
  50. Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ, Bowdish KS. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol 2008 Jan 15;180(2):699-705.


Please see full Prescribing Information and Important Safety Information for Soliris® (eculizumab).